Depleting certain immune cells to improve recovery after spinal cord injury
Macrophage Depletion Therapy for Spinal Cord Injury
This study is looking at how removing certain immune cells might help people recover better from spinal cord injuries by improving movement and reducing pain, and it aims to find out if this treatment can lead to better outcomes for those affected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-11001939 on NIH RePORTER |
What this research studies
This research investigates the effects of macrophage depletion therapy on recovery from spinal cord injury (SCI). It aims to understand how removing specific immune cells can lead to better functional outcomes, such as improved movement and reduced pain. The study will utilize clinically relevant measures to assess changes in bodily functions after treatment, focusing on the impact of injury level and the long-term effects of this therapy. By translating findings from animal models to potential human applications, the research seeks to fill a critical gap in current SCI treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have recently suffered a spinal cord injury and are experiencing significant functional impairments.
Not a fit: Patients with chronic spinal cord injuries or those who do not have significant functional impairments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that significantly improve recovery and quality of life for individuals with spinal cord injuries.
How similar studies have performed: Previous research has shown promising results with macrophage depletion in animal models, indicating potential for success in human applications.
Where this research is happening
Lexington, United States
- University of Kentucky — Lexington, United States (Active)
Researchers
- Principal investigator: Gensel, John C — University of Kentucky
- Study coordinator: Gensel, John C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.